Randomized Multicenter Cross-over Study to Compare the Effect of Physioneal 35 to 40 on the Protein Metabolism (NephropaedPD01)

• ClinicalTrials.gov Identifier: NCT00776191
• Recruitment Status: Terminated
• First Posted: October 21, 2008
• Last Update Posted: June 4, 2015
• Sponsor: University of Erlangen-Nürnberg Medical School
• Information provided by (Responsible Party): University of Erlangen-Nürnberg Medical School

Study Description

Brief Summary:

The purpose of this study is to demonstrate an increase in protein metabolism during treatment with Physioneal 35® (containing lactate 10 mmol/l, calcium 1.75 mmol/l) compared to treatment with Physioneal 40® (containing lactate 15 mmol/l, calcium 1.25 mmol/l) in children and adolescents with end stage renal failure receiving peritoneal dialysis.

Condition or disease	Intervention/treatment	Phase
Endstage Renal Disease	Drug: Physioneal 35; Drug: Physioneal 40	Phase 4

Detailed Description:

• Fat oxidation (13C-enrichment in expiration breath samples for U-C13-algae turnover)
• Growth markers (plasma levels of IgF-1, IgF-BP3, leptin)
• Biochemical markers of anabolism (plasma levels of total protein, albumin, transferrin)
• Serum thyroid function (fT3, fT4, TSH)
• Serum lipid status
• Serum markers of calcium/phosphate metabolism (PTH, calcium, ionized calcium, phosphate, alkaline phosphatase)
• Prevalence of metabolic acidosis/ alkalosis (venous sample), serum lactate
• Safety parameters (such as normalized weekly Kt/v, parameters of glucose metabolism, parameters of hepatic function, parameters of calcium-phosphate-metabolism, physical examination incl. standing height, weight, assessment of complications related to peritoneal dialysis as peritonitis, exit infections and inguinal hernia)
• Body composition (lean body mass and body fat mass/fluid)

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 5 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Randomized, Multicenter Cross-over Study in Investigating the Effect of Bicarbonate-based Solutions (Physioneal 35 vs. 40) on Protein Metabolism in Children and Adolescents on Chronic Peritoneal Dialysis
• Study Start Date: September 2008
• Actual Primary Completion Date: May 2012
• Actual Study Completion Date: May 2012

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Physioneal 35 vs. 40; Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks, followed by Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks.	Drug: Physioneal 35; Physioneal 35® for eight weeks, followed by Physioneal 40® for eight weeks; Other Name: Nephropaed-PD-01/B
Active Comparator: Physioneal 40 vs. 35; Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks followed by Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks	Drug: Physioneal 40; Physioneal 40® for eight weeks followed by Physioneal 35® for eight weeks; Other Name: Nephropaed-PD-01/B

Outcome Measures

Primary Outcome Measures :

1. To demonstrate an increase in protein metabolism during treatment with Physioneal 35® compared to treatment with Physioneal 40® in children and adolescents with end stage renal failure receiving peritoneal dialysis. [ Time Frame: 16 weeks ]

Secondary Outcome Measures :

1. To demonstrate a improved Fat oxidation during treatment with Physioneal compared to treatment with Physioneal 40® in children and adolescents with end stage renal failure receiving peritoneal dialysis. [ Time Frame: 16 weeks ]

Eligibility Criteria

• Ages Eligible for Study: 3 Months to 18 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients who are males or non-pregnant females between the ages of 3 months and 18 years.
• Patients who are on regular automated peritoneal dialysis due to end stage renal failure for at least 3 months.
• Patients and/or their parents must be capable of understanding the purpose and risks of the study.
• Patients and/or their parents (or guardians) who are willing to give written informed consent and willing to participate in and comply with the study protocol.

Exclusion Criteria:

• Use of pure lactate, amino acid or oligosaccharide solutions for peritoneal dialysis
• Peritonitis episode less than 6 weeks before enrolment
• Hypercalcemia (serum) > 2.75 mmol/l in three independent measurements during 10 days
• Severe secondary hyperthyroidism (iPTH > 500 ng/l)
• Renal anemia with hemoglobin (blood) < 10 mg/dl
• Impaired hepatic function (AST/SGOT or ALT/SGPT > 2 times the upper limit of the reference range)
• Patients who are participating in another study that requires Ethics Committee approval. Non-interventional studies are permitted.
• Pregnant female patients, females of childbearing potential who are unwilling or unable to use adequate contraception methods.
• Severe respiratory insufficiency
• Malnourishment (body weight < -2.5 SDS for height and gender) or severe deterioration of fat metabolism
• Patients with a history of malignancy of any organ system, treated or untreated

• Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of the investigational product and the comparator, including

  • Major deterioration of the abdominal wall (e.g. dermal infections or burns, hernia)
  • Major deterioration of the abdominal cavity (e.g. ascites, ileus, adhesions, bowel perforation, defects of the diaphragm, tumours)
• Patients with a history of viral infections such as HIV or hepatitis B, C.

Contacts and Locations

Locations

Germany

Pediatric Nephrology, Universiy Children's Hospital

Cologne, Germany

Dept. of Pediatric Nephrology, University Hospital Erlangen

Erlangen, Germany

Dept. of Pediatric Nephrology, University of Hannover

Hannover, Germany, 30625

Dept. of Nephrology, children´s hospital Memmingen

Memmingen, Germany, 87700

Dept. of Nephrology, University of Rostock

Rostock, Germany, 18057

Sponsors and Collaborators

University of Erlangen-Nürnberg Medical School

Investigators

• Principal Investigator: Joerg Doetsch, Prof. Dr.; University Hospital Erlangen, Department of Pediatrics University Hospital Koeln

More Information

• Responsible Party: University of Erlangen-Nürnberg Medical School
• ClinicalTrials.gov Identifier: NCT00776191
• Other Study ID Numbers: 2005-005434-12
• First Posted: October 21, 2008
• Last Update Posted: June 4, 2015
• Last Verified: June 2015

Keywords provided by University of Erlangen-Nürnberg Medical School:

Physioneal 35; Physioneal 40; children; chronic peritoneal dialysis

Additional relevant MeSH terms:

Kidney Failure, Chronic; Kidney Diseases; Urologic Diseases; Renal Insufficiency, Chronic; Renal Insufficiency